Related Experiment Video
Updated: Jul 27, 2025
Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives
Published on: September 16, 2021
Scalable cryopreservation of infectious Cryptosporidium hominis oocysts by vitrification
Justyna J Jaskiewicz1,2, Denise Ann E Dayao2, Donald Girouard2
1BioMEMS Resource Center, Center for Engineering in Medicine and Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, and Shriners Children`s Boston, Boston, Massachusetts, United States of America.
Abstract:
Cryptosporidium hominis is a serious cause of childhood diarrhea in developing countries. The development of therapeutics is impeded by major technical roadblocks including lack of cryopreservation and simple culturing methods. This impacts the availability of optimized/standardized singular sources of infectious parasite oocysts for research and human challenge studies. The human C. hominis TU502 isolate is currently propagated in gnotobiotic piglets in only one laboratory, which limits access to oocysts. Streamlined cryopreservation could enable creation of a biobank to serve as an oocyst source for research and distribution to other investigators requiring C. hominis. Here, we report cryopreservation of C. hominis TU502 oocysts by vitrification using specially designed specimen containers scaled to 100 μL volume. Thawed oocysts exhibit ~70% viability with robust excystation and 100% infection rate in gnotobiotic piglets. The availability of optimized/standardized sources of oocysts may streamline drug and vaccine evaluation by enabling wider access to biological specimens.
Insights
Researchers cryopreserved Cryptosporidium hominis oocysts using vitrification. This breakthrough enables a biobank for infectious parasite research and drug development, overcoming previous limitations in oocyst availability.
Area of Science:
- Parasitology
- Infectious Diseases
- Biotechnology
Background:
- Cryptosporidium hominis causes significant childhood diarrhea in developing nations.
- Lack of cryopreservation and simple culturing methods hinders therapeutic development.
- Limited availability of infectious Cryptosporidium hominis oocysts restricts research and human challenge studies.
Purpose of the Study:
- To develop a streamlined cryopreservation method for Cryptosporidium hominis TU502 oocysts.
- To establish a reliable and accessible source of infectious oocysts for research.
- To overcome technical roadblocks impeding the development of C. hominis therapeutics.
Main Methods:
- Vitrification of Cryptosporidium hominis TU502 oocysts using 100 μL volume specimen containers.
- Assessment of oocyst viability post-thawing.
- Evaluation of excystation rates and infectivity in gnotobiotic piglets.
Main Results:
- Successfully cryopreserved Cryptosporidium hominis TU502 oocysts via vitrification.
- ~70% viability observed in thawed oocysts.
- Demonstrated robust excystation and 100% infection rate in gnotobiotic piglets post-thawing.
Conclusions:
- Streamlined cryopreservation of C. hominis oocysts is feasible using vitrification.
- This method enables the creation of a biobank for standardized oocyst distribution.
- Enhanced oocyst availability is expected to accelerate drug and vaccine evaluations for cryptosporidiosis.
